We are live on ! Find out more
ANIP icon

ANI Pharmaceuticals
ANIP

196 hedge funds and large institutions have $704M invested in ANI Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 82 increasing their positions, 51 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

62% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 13

61% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 51

30% more capital invested

Capital invested by funds: $543M → $704M (+$161M)

16% more call options, than puts

Call options by funds: $7.06M | Put options by funds: $6.07M

6.23% more ownership

Funds ownership: 65% → 71.23% (+6.2%)

3% more funds holding

Funds holding: 190 → 196 (+6)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
196
Holders Change
+6
Holders Change %
+3.16%
% of All Funds
4.26%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
21
Increased
82
Reduced
51
Closed
13
Calls
$7.06M
Puts
$6.07M
Net Calls
+$997K
Net Calls Change
-$2.6M

Top Buyers

1
Invesco
Invesco
Georgia
+$8.11M
2
Deutsche Bank
Deutsche Bank
Germany
+$6.89M
3
Nomura Holdings
Nomura Holdings
Japan
+$6.79M
4
Renaissance Technologies
Renaissance Technologies
New York
+$6.32M
5
N
Nuveen
North Carolina
+$6.12M

Top Sellers

1
SG Americas Securities
SG Americas Securities
New York
-$4.21M
2
WAM
Weiss Asset Management
Massachusetts
-$2.31M
3
Charles Schwab
Charles Schwab
California
-$1.51M
4
CCM
Cadence Capital Management
Massachusetts
-$1.45M
5
PAM
Panagora Asset Management
Massachusetts
-$1.16M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$118M +$4.95M +69,621 +5%
Vanguard Group
2
Vanguard Group
Pennsylvania
$46.4M +$915K +12,859 +2%
MP
3
Mangrove Partners
Connecticut
$45.2M – – –
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$44.2M +$173K +2,434 +0.5%
Nomura Holdings
5
Nomura Holdings
Japan
$31.1M +$6.79M +95,462 +34%
Deutsche Bank
6
Deutsche Bank
Germany
$26.1M +$6.89M +96,892 +44%
First Manhattan
7
First Manhattan
New York
$24.2M +$3.89M +54,686 +23%
State Street
8
State Street
Massachusetts
$23.7M +$1.68M +23,653 +9%
Renaissance Technologies
9
Renaissance Technologies
New York
$23.7M +$6.32M +88,900 +45%
ICOM
10
Investment Counselors of Maryland
Maryland
$23M +$220K +3,100 +1%
Invesco
11
Invesco
Georgia
$17.6M +$8.11M +114,084 +114%
CCM
12
Consonance Capital Management
New York
$11.8M – – –
GACM
13
Global Alpha Capital Management
Quebec, Canada
$11.7M +$3.27M +45,935 +48%
MCM
14
Matarin Capital Management
New York
$11.5M +$312K +4,384 +3%
PFC
15
Phocas Financial Corp
California
$10.5M -$966K -13,586 -10%
HRCM
16
Hawk Ridge Capital Management
California
$10.2M – – –
Northern Trust
17
Northern Trust
Illinois
$9.79M +$171K +2,404 +2%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$9.54M +$715K +10,052 +9%
LSV Asset Management
19
LSV Asset Management
Illinois
$9.37M +$2.29M +32,215 +39%
Ameriprise
20
Ameriprise
Minnesota
$9.23M -$365K -5,130 -4%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$8.98M +$316K +4,442 +4%
Charles Schwab
22
Charles Schwab
California
$8.35M -$1.51M -21,264 -17%
RIM
23
Ranger Investment Management
Texas
$7.41M +$258K +3,623 +4%
TAM
24
THB Asset Management
Connecticut
$7.34M +$4.54M +63,874 +251%
N
25
Nuveen
North Carolina
$7.07M +$6.12M +86,019 New
1
2 3 4 5

ANIP Hedge Fund Activity: Q2 2019 in Review

196 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q2 2019, worth a combined $704M — up 30% from $543M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new ANIP positions and 13 closed out — a net gain of 8 holders — while 82 added to existing stakes and 51 trimmed.

The largest buyer was Invesco, adding an estimated $8.11M. The largest seller was SG Americas Securities, cutting an estimated $4.21M.

  • 196 institutional investors held ANI Pharmaceuticals (ANIP) as of Q2 2019, up from 190 in Q1 2019.
  • Funds reported $704M of ANI Pharmaceuticals stock for Q2 2019, up 30% quarter-over-quarter.
  • 21 funds opened new ANI Pharmaceuticals positions in Q2 2019 and 13 closed out, a net change of +8 holders.
  • The largest ANI Pharmaceuticals buyer in Q2 2019 was Invesco, an estimated $8.11M added.
  • The largest ANI Pharmaceuticals seller in Q2 2019 was SG Americas Securities, an estimated $4.21M sold.

Based on aggregated 13F filings for Q2 2019.